Copertina

Assessing EAU criteria for high‐risk upper tract urothelial carcinoma

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Mahmoud Farzat, Sami‐Ramzi Leyh‐Bannurah, Mykyta Kachanov, Florian M. Wagenlehner
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	BJUI Compass
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Cumulative incidence and risk factors for recurrence of upper tract urothelial carcinoma in patients undergoing radical cystectomy
di: Ryo Yamashita, et al.
Pubblicazione: (2024)

Waiting time in diagnosis and extirpative surgery and association with survival and stage progression in upper tract urothelial carcinomas
di: Fredrik Liedberg, et al.
Pubblicazione: (2025)

Predictive role of ABC transporters in the efficacy of enfortumab vedotin for urothelial carcinoma
di: Toshiki Kijima, et al.
Pubblicazione: (2025)

Reduced p63 expression is linked to unfavourable prognosis in muscle‐invasive urothelial carcinoma of the bladder
di: Kira Furlano, et al.
Pubblicazione: (2024)

Malignant upper urinary tract obstruction in cancer patients: A systematic review
di: Max Shah, et al.
Pubblicazione: (2024)

Competing risk of death in patients with low, intermediate and high risk of recurrence after radical surgery for clear cell renal cell carcinoma
di: Anna Brännbäck, et al.
Pubblicazione: (2025)

Validation of the diagnostic accuracy of a urine‐based DNA methylation marker test in patients with upper urinary tract lesions
di: Christian Daniel Fankhauser, et al.
Pubblicazione: (2026)

Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer
di: Mohammed Al‐Zubaidi, et al.
Pubblicazione: (2024)

Multidisciplinary meetings for lower urinary tract symptoms and benign prostate hyperplasia
di: Emilien Seizilles de Mazancourt, et al.
Pubblicazione: (2025)

PSMA PET/CT findings in high‐risk biochemical recurrence after local treatment of prostate cancer
di: Nicole Handa, et al.
Pubblicazione: (2025)

Association of erectile dysfunction and male lower urinary tract symptoms in a Japanese cross‐sectional survey
di: Katsuya Yamaguchi, et al.
Pubblicazione: (2026)

Influences on androgen deprivation therapy prescribing before surgery in high‐risk prostate cancer
di: Jennifer Dunsmore, et al.
Pubblicazione: (2024)

Long non‐coding RNAs define favourable biology in high‐risk non‐muscle‐invasive bladder cancer
di: Rachel Weng, et al.
Pubblicazione: (2025)

Treatment outcomes of multidisciplinary management of recurrent urinary tract infections: A 2‐year experience in a dedicated complex‐UTI clinic
di: Pragnitha Chitteti, et al.
Pubblicazione: (2026)

Utilization of cardiopulmonary bypass at radical nephrectomy for renal cell carcinoma with tumour thrombus
di: Chalairat Suk‐Ouichai, et al.
Pubblicazione: (2024)

Extended versus limited pelvic lymph node dissection and long‐term outcomes in high‐risk prostate cancer before radiotherapy
di: Georgios Daouacher, et al.
Pubblicazione: (2026)

Peak early‐phase enhancement ratio on contrast‐enhanced MRI to differentiate chromophobe renal cell carcinoma from oncocytoma
di: Deanna Thorson, et al.
Pubblicazione: (2025)

Recurrence patterns following nephrectomy for renal cell carcinoma in a Danish nationwide cohort
di: Goran Bencina, et al.
Pubblicazione: (2024)

Long‐term outcomes after cytoreductive partial nephrectomy for metastatic renal cell carcinoma
di: Andrea Lopez Sanmiguel, et al.
Pubblicazione: (2026)

Robotic‐assisted approaches to urachal carcinoma: A comprehensive systematic review of the safety and efficacy outcomes
di: Caio Vinícius Suartz, et al.
Pubblicazione: (2024)

Neoadjuvant tislelizumab plus pazopanib in renal cell carcinoma with venous tumour thrombus: A retrospective study
di: Diliyaer Dilixiati, et al.
Pubblicazione: (2025)

Machine learning analysis for detecting late recurrence and loss to follow‐up after renal cell carcinoma surgery
di: Kodai Sato, et al.
Pubblicazione: (2024)

Genomic prostate score and treatment selection in favourable intermediate‐risk prostate cancer
di: Eric Margolis, et al.
Pubblicazione: (2025)

Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study
di: Sho Kiyota, et al.
Pubblicazione: (2024)

Active migration technique in RIRS for 1‐ to 2‐cm middle and upper ureteral stones in a prospective randomized controlled study
di: Ping Liang, et al.
Pubblicazione: (2026)

Nephrolithiasis risk factors for obese patients on 24‐hour urine collection metabolic evaluation
di: Mark I. Sultan, et al.
Pubblicazione: (2025)

Patient satisfaction and scope size of flexible ureteroscopy for upper urinary stones: A comparative study, multivariate analysis and subjective and objective evaluations
di: Ihab A. Hekal, et al.
Pubblicazione: (2026)

Cinematic rendering of 18 F‐DCFPyL PET/CT fusion data in a patient with metastatic clear cell renal cell carcinoma
di: Steven P. Rowe, et al.
Pubblicazione: (2024)

Developing sustainable Emergency Urology Simulation Training in sub‐Saharan Africa
di: William James Gladstone Finch, et al.
Pubblicazione: (2026)

Haematuria cancer risk score as a predictor of muscle‐invasive bladder cancer
di: Serdar Turan, et al.
Pubblicazione: (2025)

Ureteroenteric strictures after cystectomy: Side‐specific risk factors and radiological assessment
di: Simone Buchardt Brandt, et al.
Pubblicazione: (2024)

Omission of contralateral biopsies in unilateral MRI‐suspicious prostate cancer has minimal impact on clinical risk assessment
di: Stijn M. van den Bosch, et al.
Pubblicazione: (2026)

Extracapsular extension risk assessment using an artificial intelligence prostate cancer mapping algorithm
di: Alan Priester, et al.
Pubblicazione: (2024)

First validation of the Prostatype® P‐score in an Asian cohort: Improving risk stratification for prostate cancer
di: See‐Tong Pang, et al.
Pubblicazione: (2025)

Oncological outcomes post focal low‐dose‐rate brachytherapy in low‐intermediate risk prostate cancer
di: Mohammadmehdi Adhami, et al.
Pubblicazione: (2026)

Development of a novel risk model to predict CRPC progression following IMRT: Implications for tailoring treatment intensity
di: Takashi Ogata, et al.
Pubblicazione: (2025)

Quantification of perineural invasion on prostate biopsy improves risk stratification in biopsy Grade Group 2–3 cancer
di: Yuki Teramoto, et al.
Pubblicazione: (2026)

Increased risk of bleeding during and after HoLEP in patients with prostate cancer: A multicentre comparative cohort study
di: Angelo Porreca, et al.
Pubblicazione: (2025)

AI‐driven preoperative risk assessment in kidney cancer surgery: A comparative feasibility study of machine learning models
di: Julia Mühlbauer, et al.
Pubblicazione: (2025)

Acu‐URO17 is a highly sensitive and specific bladder cancer biomarker
di: Liwu Guo, et al.
Pubblicazione: (2024)